ATC Group: H01CC Anti-gonadotropin-releasing hormones

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of H01CC in the ATC hierarchy

Level Code Title
1 H Systemic hormonal preparations, excl. Sex hormones and insulins
2 H01 Pituitary and hypothalamic hormones and analogues
3 H01C Hypothalamic hormones
4 H01CC Anti-gonadotropin-releasing hormones

Group H01CC contents

Code Title
H01CC01 Ganirelix
H01CC02 Cetrorelix
H01CC03
H01CC04
H01CC53
H01CC54

Active ingredients in H01CC

Active Ingredient Description
Cetrorelix

Cetrorelix is a synthetic decapeptide with gonadotropin-releasing hormone (GnRH) antagonistic activity. GnRH induces the production and release of luteinizing hormone (LH) and follicle stimulating hormone (FSH) from the gonadotrophic cells of the anterior pituitary. Due to a positive estradiol (E2) feedback at midcycle, GnRH liberation is enhanced resulting in an LH-surge. This LH-surge induces the ovulation of the dominant follicle, resumption of oocyte meiosis and subsequently luteinization as indicated by rising progesterone levels. Cetrorelix competes with natural GnRH for binding to membrane receptors on pituitary cells and thus controls the release of LH and FSH in a dose-dependent manner. Cetrorelix binds to the gonadotropin releasing hormone receptor and acts as a potent inhibitor of gonadotropin secretion. It competes with natural GnRH for binding to membrane receptors on pituitary cells and thus controls the release of LH and FSH in a dose-dependent manner. Cetrotide (cetrorelix acetate for injection) is indicated for the inhibition of premature LH surges in women undergoing controlled ovarian stimulation.

Elagolix

Elagolix is a GnRH receptor antagonist that inhibits endogenous GnRH signaling by binding competitively to GnRH receptors in the pituitary gland. Administration of elagolix results in dose-dependent suppression of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), leading to decreased blood concentrations of the ovarian sex hormones, estradiol and progesterone.

Ganirelix

Ganirelix is a GnRH antagonist, which modulates the hypothalamic-pituitary-gonadal axis by competitive binding to the GnRH receptors in the pituitary gland. As a result a rapid, profound, reversible suppression of endogenous gonadotrophins occurs, without initial stimulation as induced by GnRH agonists.

Linzagolix

Linzagolix is a selective, non-peptide gonadotropin-releasing hormone (GnRH) receptor antagonist that inhibits endogenous GnRH signalling by binding competitively to GnRH receptors in the pituitary gland, thereby modulating the hypothalamic-pituitary-gonadal axis.

Related product monographs

Title Information Source Document Type  
CETROTIDE Powder and solvent for solution for injection European Medicines Agency (EU) MPI, EU: SmPC
FYREMADEL Solution for injection in pre-filled syringe Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
ORGALUTRAN Solution for injection European Medicines Agency (EU) MPI, EU: SmPC
ORILISSA Film-coated tablet FDA, National Drug Code (US) MPI, US: SPL/PLR
RYEQO Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC
YSELTY Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC